sarepta therapeutics - Search News

News

gene, Sarepta

Sarepta shares crash as second patient dies after receiving its gene therapy

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys, raising doubts on the safety and future demand for the treatment.

GlobalData on MSN · 17h

Sarepta and Roche halt DMD gene therapy’s use after second death

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The Washington Post on MSN · 8h

Biotech pauses trial after second patient death linked to gene therapy

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

Sarepta reports 2nd case of liver failure death

Seeking Alpha · 16h

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.

MarketWatch · 18h

Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys

Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy treatment Elevidys. Shares were trading around $20.61. The stock is down 70% on the year.

Reuters on MSN · 1d

Sarepta reports second case of liver failure death after its gene therapy treatment

Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy

9hon MSN

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of ...

23h

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

18h

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

STAT10h

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

Managed Healthcare Executive14h

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

16h

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS ...

Stocktwits on MSN15h

Sarepta Therapeutics Stock Plunges On Multiple Downgrades Following Patient Death: Retail Questions ‘Crazy’ Price Targets

Shares of Sarepta Therapeutics, Inc. (SRPT) traded 46% lower on Monday morning after multiple analysts downgraded the stock ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

gene, Sarepta

Sarepta reports 2nd case of liver failure death

Related topics